Session

H. pylori at interfaces (Posters)

TIME TRENDS AND EFFECTIVENESS OF BISMUTH TREATMENT FOR HELICOBACTER PYLORI INFECTION: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG) DURING 2013-2021
TIME TRENDS AND EFFECTIVENESS OF BISMUTH TREATMENT FOR HELICOBACTER PYLORI INFECTION: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG) DURING 2013-2021

H. pylori at interfaces (Posters)  et al.

PROFILING THE HEALTHY HUMAN VOCOME – UNIQUE INSIGHTS INTO ENDOGENOUS AND EXOGENOUS (GUT MICROBIAL) METABOLISM VIA DETECTION OF VOLATILE ORGANIC COMPOUNDS ON BREATH.
PROFILING THE HEALTHY HUMAN VOCOME – UNIQUE INSIGHTS INTO ENDOGENOUS AND EXOGENOUS (GUT MICROBIAL) METABOLISM VIA DETECTION OF VOLATILE ORGANIC COMPOUNDS ON BREATH.

H. pylori at interfaces (Posters)  et al.

GASTRIC MICROBIOTA GENDER DIFFERENCES IN HEALTHY STOMACH AND AUTOIMMUNE ATROPHIC GASTRITIS
GASTRIC MICROBIOTA GENDER DIFFERENCES IN HEALTHY STOMACH AND AUTOIMMUNE ATROPHIC GASTRITIS

H. pylori at interfaces (Posters)  et al.

EXPERIENCE WITH SINGLE-CAPSULE BISMUTH QUADRUPLE THERAPY IN 8,000 PATIENTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
EXPERIENCE WITH SINGLE-CAPSULE BISMUTH QUADRUPLE THERAPY IN 8,000 PATIENTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

H. pylori at interfaces (Posters)  et al.

14-DAY TAILORED PCR-GUIDED TRIPLE THERAPY VERSUS 14-DAY NON-BISMUTH CONCOMITANT QUADRUPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION: A MULTICENTER, OPEN-LABEL RANDOMIZED CONTROLLED TRIAL, THE HEPYSE TRIAL
14-DAY TAILORED PCR-GUIDED TRIPLE THERAPY VERSUS 14-DAY NON-BISMUTH CONCOMITANT QUADRUPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION: A MULTICENTER, OPEN-LABEL RANDOMIZED CONTROLLED TRIAL, THE HEPYSE TRIAL

H. pylori at interfaces (Posters)  et al.

ROLE OF PROTON PUMP INHIBITORS DOSAGE IN THE EFFECTIVENESS OF HELICOBACTER PYLORI ERADICATION TREATMENTS: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ROLE OF PROTON PUMP INHIBITORS DOSAGE IN THE EFFECTIVENESS OF HELICOBACTER PYLORI ERADICATION TREATMENTS: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

H. pylori at interfaces (Posters)  et al.

THE ROLE OF PROBIOTICS IN THE EFFECTIVENESS OF TREATMENT AGAINST HELICOBACTER PYLORI: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)
THE ROLE OF PROBIOTICS IN THE EFFECTIVENESS OF TREATMENT AGAINST HELICOBACTER PYLORI: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)

H. pylori at interfaces (Posters)  et al.

EFFICACY OF STANDARD TRIPLE THERAPY WITH STATIN COMPARED WITH STANDARD TRIPLE THERAPY IN HELICOBACTER PYLORI ERADICATION: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
EFFICACY OF STANDARD TRIPLE THERAPY WITH STATIN COMPARED WITH STANDARD TRIPLE THERAPY IN HELICOBACTER PYLORI ERADICATION: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL

H. pylori at interfaces (Posters)  et al.

ROLE OF HELICOBACTER PYLORI AS A PATHOGEN OR MUTUALIST IN COLOMBIA
ROLE OF HELICOBACTER PYLORI AS A PATHOGEN OR MUTUALIST IN COLOMBIA

H. pylori at interfaces (Posters)  et al.

ROLE OF HELICOBACTER PYLORI AS A PATHOGEN OR MUTUALIST IN COLOMBIA
ROLE OF HELICOBACTER PYLORI AS A PATHOGEN OR MUTUALIST IN COLOMBIA

PROFILING THE HEALTHY HUMAN VOCOME – UNIQUE INSIGHTS INTO ENDOGENOUS AND EXOGENOUS (GUT MICROBIAL) METABOLISM VIA DETECTION OF VOLATILE ORGANIC COMPOUNDS ON BREATH.
PROFILING THE HEALTHY HUMAN VOCOME – UNIQUE INSIGHTS INTO ENDOGENOUS AND EXOGENOUS (GUT MICROBIAL) METABOLISM VIA DETECTION OF VOLATILE ORGANIC COMPOUNDS ON BREATH.

GASTRIC MICROBIOTA GENDER DIFFERENCES IN HEALTHY STOMACH AND AUTOIMMUNE ATROPHIC GASTRITIS
GASTRIC MICROBIOTA GENDER DIFFERENCES IN HEALTHY STOMACH AND AUTOIMMUNE ATROPHIC GASTRITIS

14-DAY TAILORED PCR-GUIDED TRIPLE THERAPY VERSUS 14-DAY NON-BISMUTH CONCOMITANT QUADRUPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION: A MULTICENTER, OPEN-LABEL RANDOMIZED CONTROLLED TRIAL, THE HEPYSE TRIAL
14-DAY TAILORED PCR-GUIDED TRIPLE THERAPY VERSUS 14-DAY NON-BISMUTH CONCOMITANT QUADRUPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION: A MULTICENTER, OPEN-LABEL RANDOMIZED CONTROLLED TRIAL, THE HEPYSE TRIAL

THE ROLE OF PROBIOTICS IN THE EFFECTIVENESS OF TREATMENT AGAINST HELICOBACTER PYLORI: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)
THE ROLE OF PROBIOTICS IN THE EFFECTIVENESS OF TREATMENT AGAINST HELICOBACTER PYLORI: RESULTS OF THE EUROPEAN REGISTRY ON THE MANAGEMENT OF HELICOBACTER PYLORI INFECTION (HP-EUREG)

TIME TRENDS AND EFFECTIVENESS OF BISMUTH TREATMENT FOR HELICOBACTER PYLORI INFECTION: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG) DURING 2013-2021
TIME TRENDS AND EFFECTIVENESS OF BISMUTH TREATMENT FOR HELICOBACTER PYLORI INFECTION: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG) DURING 2013-2021

EXPERIENCE WITH SINGLE-CAPSULE BISMUTH QUADRUPLE THERAPY IN 8,000 PATIENTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)
EXPERIENCE WITH SINGLE-CAPSULE BISMUTH QUADRUPLE THERAPY IN 8,000 PATIENTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG)

ROLE OF PROTON PUMP INHIBITORS DOSAGE IN THE EFFECTIVENESS OF HELICOBACTER PYLORI ERADICATION TREATMENTS: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)
ROLE OF PROTON PUMP INHIBITORS DOSAGE IN THE EFFECTIVENESS OF HELICOBACTER PYLORI ERADICATION TREATMENTS: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

EFFICACY OF STANDARD TRIPLE THERAPY WITH STATIN COMPARED WITH STANDARD TRIPLE THERAPY IN HELICOBACTER PYLORI ERADICATION: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL
EFFICACY OF STANDARD TRIPLE THERAPY WITH STATIN COMPARED WITH STANDARD TRIPLE THERAPY IN HELICOBACTER PYLORI ERADICATION: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL

Item 1 - 18 / 18
1